论文部分内容阅读
目的观察门冬胰岛素30(BIAsp30)一日2次和3次皮下注射方案对初诊2型糖尿病患者的疗效。方法 73例初诊2型糖尿病患者按半随机原则分为A组和B组,A组予BIAsp30一日2次皮下注射,B组予BIAsp30一日3次皮下注射,观察两组患者空腹血糖(FPG)、餐后血糖(PBG)、糖化血红蛋白(HbA1c)及低血糖发生率的差异等。结果与治疗前相比,治疗3个月两组患者血糖水平均显著降低,且治疗后B组早餐后、午餐后、晚餐前及晚餐后血糖水平均低于A组;同时B组PBG水平显著低于A组;B组低血糖发生率也低于A组。结论门冬胰岛素30一日3次治疗初诊2型糖尿病患者疗效显著,安全性高。
Objective To observe the efficacy of insulin aspart 30 (BIAsp30) twice a day and 3 subcutaneous injections on newly diagnosed type 2 diabetic patients. Methods Seventy-three patients with newly diagnosed type 2 diabetes were divided into two groups according to the principle of semi-randomization: group A and group B, group A with BIAsp30 subcutaneously twice a day, group B with BIAsp30 subcutaneously three times a day, and the fasting blood glucose (FPG) ), Postprandial blood glucose (PBG), glycosylated hemoglobin (HbA1c) and the incidence of hypoglycemia and so on. Results Compared with those before treatment, the blood glucose levels in both groups were significantly decreased after 3 months of treatment, and the blood glucose levels in group B after breakfast, after lunch, before dinner and after dinner were lower than those in group A; meanwhile, the level of PBG in group B was significantly Lower than A group; B group also lower than the incidence of hypoglycemia A group. Conclusion Aspart 30 insulin three times a day treatment of newly diagnosed type 2 diabetes patients with significant efficacy and safety.